How microfluidic diffusional sizing can enhance your protein assays

Published: 30-Aug-2024

MDS can enhance the information gained from an assay experiment and allow the timely and guided production of novel protein and antibody-based therapeutics

You need to be a subscriber to read this article.
Click here to find out more.

Microfluidic Diffusional Sizing (MDS) is a novel technology which can be used to measure binding affinity and characterise protein interactions. MDS is complementary to current approaches such as surface plasmon resonance (SPR) and bio-layer interferometry (BLI) as interactions are monitored in solution, rather than on a sensor surface. Performing measurements in solution enables the analysis of samples that cannot be readily analysed using surface-based approaches. 

In this article, Dr Sean Devenish, the Chief Scientist at Fluidic Sciences, discusses how the MDS technology can enhance the assay development process. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like